HC Wainwright Has Optimistic Outlook of enGene Q4 Earnings

Key Points

• HC Wainwright raised its Q4 2025 earnings per share estimate for enGene to ($0.48), up from the previous estimate of ($0.54), while maintaining a "Buy" rating and a price target of $25.00.
• enGene's recent earnings report indicated a per share loss of ($0.51), slightly below the consensus estimate of ($0.48).
• Currently, enGene has attracted significant institutional interest, with approximately 64.16% of its shares held by institutional investors and hedge funds.

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Research analysts at HC Wainwright increased their Q4 2025 earnings per share (EPS) estimates for shares of enGene in a research report issued to clients and investors on Monday, September 8th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.48) per share for the quarter, up from their prior estimate of ($0.54). HC Wainwright currently has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for enGene's current full-year earnings is ($1.56) per share.

enGene (NASDAQ:ENGN - Get Free Report) last posted its earnings results on Tuesday, June 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03).

enGene Stock Up 13.3%

ENGN stock opened at $6.29 on Thursday. The company has a current ratio of 12.66, a quick ratio of 12.66 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $321.42 million, a PE ratio of -3.81 and a beta of -0.39. enGene has a 1-year low of $2.65 and a 1-year high of $11.00. The business's 50 day simple moving average is $4.04 and its 200 day simple moving average is $4.13.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Paloma Partners Management Co acquired a new position in shares of enGene during the 2nd quarter worth approximately $38,000. Affinity Asset Advisors LLC bought a new stake in enGene in the 2nd quarter valued at $280,000. Cresset Asset Management LLC bought a new stake in enGene in the 2nd quarter valued at $36,000. Adage Capital Partners GP L.L.C. boosted its stake in enGene by 2.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company's stock valued at $7,041,000 after purchasing an additional 41,874 shares during the period. Finally, ADAR1 Capital Management LLC bought a new stake in enGene in the 1st quarter valued at $107,000. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.